Polypharmacy is Associated with an Increased Risk of Bleeding in Elderly Patients with Venous Thromboembolism

Overview

Journal J Gen Intern Med

Publisher Springer

Specialty General Medicine

Date 2014 Aug 22

PMID 25143224

Citations 25

Authors

Waltraud Leiss

Marie Mean

Andreas Limacher

Marc Righini

Kurt Jaeger

Hans-Jurg Beer

Joseph Osterwalder

Beat Frauchiger

Christian M Matter

Nils Kucher

Anne Angelillo-Scherrer

Jacques Cornuz

Martin Banyai

Bernhard Lammle

Marc Husmann

Michael Egloff

Markus Aschwanden

Nicolas Rodondi

Drahomir Aujesky

Affiliations

Soon will be listed here.

Abstract

Background: Polypharmacy, defined as the concomitant use of multiple medications, is very common in the elderly and may trigger drug-drug interactions and increase the risk of falls in patients receiving vitamin K antagonists.

Objective: To examine whether polypharmacy increases the risk of bleeding in elderly patients who receive vitamin K antagonists for acute venous thromboembolism (VTE).

Design: We used a prospective cohort study.

Participants: In a multicenter Swiss cohort, we studied 830 patients aged ≥ 65 years with VTE.

Main Measures: We defined polypharmacy as the prescription of more than four different drugs. We assessed the association between polypharmacy and the time to a first major and clinically relevant non-major bleeding, accounting for the competing risk of death. We adjusted for known bleeding risk factors (age, gender, pulmonary embolism, active cancer, arterial hypertension, cardiac disease, cerebrovascular disease, chronic liver and renal disease, diabetes mellitus, history of major bleeding, recent surgery, anemia, thrombocytopenia) and periods of vitamin K antagonist treatment as a time-varying covariate.

Key Results: Overall, 413 (49.8 %) patients had polypharmacy. The mean follow-up duration was 17.8 months. Patients with polypharmacy had a significantly higher incidence of major (9.0 vs. 4.1 events/100 patient-years; incidence rate ratio [IRR] 2.18, 95 % confidence interval [CI] 1.32-3.68) and clinically relevant non-major bleeding (14.8 vs. 8.0 events/100 patient-years; IRR 1.85, 95 % CI 1.27-2.71) than patients without polypharmacy. After adjustment, polypharmacy was significantly associated with major (sub-hazard ratio [SHR] 1.83, 95 % CI 1.03-3.25) and clinically relevant non-major bleeding (SHR 1.60, 95 % CI 1.06-2.42).

Conclusions: Polypharmacy is associated with an increased risk of both major and clinically relevant non-major bleeding in elderly patients receiving vitamin K antagonists for VTE.

Citing Articles

Clinical implication of anemia in older patients with dementia with lewy bodies.

Karismaz A, Soysal P, Eren R, Serin I, Bilgic I, Tanriverdi I Aging Clin Exp Res. 2025; 37(1):39.

PMID: 39964627 PMC: 11835966. DOI: 10.1007/s40520-025-02958-0.

Association between selective serotonin reuptake inhibitors use and blood transfusion risk in older adults after hip fracture: a cohort study.

Gobillot-Morisson H, Genet B, Frere C, Cohen-Bittan J, Raux M, Rollet M BMC Geriatr. 2024; 24(1):1048.

PMID: 39736543 PMC: 11686848. DOI: 10.1186/s12877-024-05634-6.

Nonvitamin K Anticoagulants: Risk of Bleeding When Interacting With Other Medications: A Cohort Study From Medicare.

Gomez-Lumbreras A, Brendle M, Moorman-Bishir K, Tan M, Malone D Clin Cardiol. 2024; 47(10):e70023.

PMID: 39360666 PMC: 11447635. DOI: 10.1002/clc.70023.

Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios.

Luca F, Oliva F, Abrignani M, Di Fusco S, Parrini I, Canale M J Clin Med. 2023; 12(18).

PMID: 37762897 PMC: 10531873. DOI: 10.3390/jcm12185955.

Polypharmacy, chronic kidney disease, and mortality among older adults: A prospective study of National Health and nutrition examination survey, 1999-2018.

Wang X, Yang C, Jiang J, Hu Y, Hao Y, Dong J Front Public Health. 2023; 11:1116583.

PMID: 37033012 PMC: 10077868. DOI: 10.3389/fpubh.2023.1116583.

References

Holbrook A, Pereira J, Labiris R, McDonald H, Douketis J, Crowther M . Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165(10):1095-106. DOI: 10.1001/archinte.165.10.1095. View

Ageno W, Agnelli G, Imberti D, Moia M, Palareti G, Pistelli R . Risk factors for venous thromboembolism in the elderly: results of the master registry. Blood Coagul Fibrinolysis. 2008; 19(7):663-7. DOI: 10.1097/MBC.0b013e3283079e58. View

Fihn S, McDonell M, Martin D, Henikoff J, Vermes D, Kent D . Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993; 118(7):511-20. DOI: 10.7326/0003-4819-118-7-199304010-00005. View

Casais P, Sanchez Luceros A, Meschengieser S, Fondevila C, Santarelli M, Lazzari M . Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol. 2000; 63(4):192-6. DOI: 10.1002/(sici)1096-8652(200004)63:4<192::aid-ajh5>3.0.co;2-k. View

Rosendaal F, van Hylckama Vlieg A, Doggen C . Venous thrombosis in the elderly. J Thromb Haemost. 2007; 5 Suppl 1:310-7. DOI: 10.1111/j.1538-7836.2007.02489.x. View

Jakobsson C, Jimenez D, Gomez V, Zamarro C, Mean M, Aujesky D . Validation of a clinical algorithm to identify low-risk patients with pulmonary embolism. J Thromb Haemost. 2010; 8(6):1242-7. DOI: 10.1111/j.1538-7836.2010.03836.x. View

Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto J, Todoli J, Samperiz A . Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008; 100(1):26-31. DOI: 10.1160/TH08-03-0193. View

Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S . Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med. 2004; 164(18):2044-50. DOI: 10.1001/archinte.164.18.2044. View

Chen Y, Dewey M, Avery A . Self-reported medication use for older people in England and Wales. J Clin Pharm Ther. 2001; 26(2):129-40. DOI: 10.1046/j.1365-2710.2001.00333.x. View

10.

Kampfen P, Mean M, Limacher A, Righini M, Jaeger K, Beer H . Risk of falls and bleeding in elderly patients with acute venous thromboembolism. J Intern Med. 2014; 276(4):378-86. DOI: 10.1111/joim.12236. View

11.

Beyth R, Quinn L, Landefeld C . Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105(2):91-9. DOI: 10.1016/s0002-9343(98)00198-3. View

12.

Slabaugh S, Maio V, Templin M, Abouzaid S . Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy. Drugs Aging. 2010; 27(12):1019-28. DOI: 10.2165/11584990-000000000-00000. View

13.

Gage B, Yan Y, E Milligan P, Waterman A, Culverhouse R, Rich M . Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151(3):713-9. DOI: 10.1016/j.ahj.2005.04.017. View

14.

Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G . Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011; 124(7):824-9. DOI: 10.1161/CIRCULATIONAHA.110.007864. View

15.

Ziere G, Dieleman J, Hofman A, Pols H, van der Cammen T, Stricker B . Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol. 2006; 61(2):218-23. PMC: 1885000. DOI: 10.1111/j.1365-2125.2005.02543.x. View

16.

Kaufman D, Kelly J, Rosenberg L, Anderson T, Mitchell A . Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002; 287(3):337-44. DOI: 10.1001/jama.287.3.337. View

17.

Abdelhafiz A, Wheeldon N . Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother. 2008; 6(1):1-11. DOI: 10.1016/j.amjopharm.2008.03.005. View

18.

Olesen J, Lip G, Hansen P, Lindhardsen J, Ahlehoff O, Andersson C . Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost. 2011; 9(8):1460-7. DOI: 10.1111/j.1538-7836.2011.04378.x. View

19.

Mean M, Aujesky D, Lammle B, Gerschheimer C, Trelle S, Angelillo-Scherrer A . Design and establishment of a biobank in a multicenter prospective cohort study of elderly patients with venous thromboembolism (SWITCO65+). J Thromb Thrombolysis. 2013; 36(4):484-91. DOI: 10.1007/s11239-013-0922-z. View

20.

Shireman T, Howard P, Kresowik T, Ellerbeck E . Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004; 35(10):2362-7. DOI: 10.1161/01.STR.0000141933.75462.c2. View